Literature DB >> 19375930

PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.

Tadashi Nariai1, Kiichi Ishiwata, Yuichi Kimura, Motoki Inaji, Toshiya Momose, Tetsuya Yamamoto, Akira Matsumura, Kenji Ishii, Kikuo Ohno.   

Abstract

INTRODUCTION: To plan the optimal BNCT for patients with malignant cerebral glioma, estimation of the ratio of boron concentration in tumor tissue against that in the surrounding normal brain (T/N ratio of boron) is important. We report a positron emission tomography (PET) imaging method to estimate T/N ratio of tissue boron concentration based on pharmacokinetic analysis of amino acid probes.
METHODS: Twelve patients with cerebral malignant glioma underwent 60 min dynamic PET scanning of brain after bolus injection of (18)F-borono-phenyl-alanine (FBPA) with timed arterial blood sampling. Using kinetic parameter obtained by this scan, T/N ratio of boron concentration elicited by one-hour constant infusion of BPA, as performed in BNCT, was simulated on Runge-Kutta algorithm. (11)C-methionine (MET) PET scan, which is commonly used in worldwide PET center as brain tumor imaging tool, was also performed on the same day to compare the image characteristics of FBPA and that of MET. RESULT: PET glioma images obtained with FBPA and MET are almost identical in all patients by visual inspection. Estimated T/N ratio of tissue boron concentration after one-hour constant infusion of BPA, T/N ratio of FBPA on static condition, and T/N ratio of MET on static condition showed significant linear correlation between each other.
CONCLUSION: T/N ratio of boron concentration that is obtained by constant infusion of BPA during BNCT can be estimated by FBPA PET scan. This ratio can also be estimated by MET-PET imaging. As MET-PET study is available in many clinical PET center, selection of candidates for BNCT may be possible by MET-PET images. Accurate planning of BNCT may be performed by static images of FBPA PET. Use of PET imaging with amino acid probes may contribute very much to establish an appropriate application of BNCT for patients with malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375930     DOI: 10.1016/j.apradiso.2009.03.061

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  10 in total

Review 1.  Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Authors:  Andrea Farolfi; Pietro Ghedini; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236

2.  18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET.

Authors:  Tadashi Watabe; Hayato Ikeda; Shushi Nagamori; Pattama Wiriyasermkul; Yoko Tanaka; Sadahiro Naka; Yasukazu Kanai; Kohei Hagiwara; Masanao Aoki; Eku Shimosegawa; Yoshikatsu Kanai; Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-22       Impact factor: 9.236

3.  Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.

Authors:  Shin-Ichi Miyatake; Motomasa Furuse; Shinji Kawabata; Takashi Maruyama; Toshihiro Kumabe; Toshihiko Kuroiwa; Koji Ono
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

4.  A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Toshihiko Kuroiwa; Susumu Miyamoto; Yoshiki Arakawa; Jun Shinoda; Kazuhiro Miwa; Toshihiko Iuchi; Koji Tsuboi; Kiyohiro Houkin; Shunsuke Terasaka; Yusuke Tabei; Hideo Nakamura; Motoo Nagane; Kazuhiko Sugiyama; Mizuhiko Terasaki; Tatsuya Abe; Yoshitaka Narita; Nobuhito Saito; Akitake Mukasa; Kuniaki Ogasawara; Takaaki Beppu; Toshihiro Kumabe; Tadashi Nariai; Naohiro Tsuyuguchi; Eiji Nakatani; Shoko Kurisu; Yoko Nakagawa; Shin-Ichi Miyatake
Journal:  Neurooncol Pract       Date:  2016-01-07

5.  Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection.

Authors:  Takahiro Morita; Hiroaki Kurihara; Kenta Hiroi; Natsuki Honda; Hiroshi Igaki; Jun Hatazawa; Yasuaki Arai; Jun Itami
Journal:  Radiat Oncol       Date:  2018-01-11       Impact factor: 3.481

6.  Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy.

Authors:  Yuki Wada; Katsumi Hirose; Takaomi Harada; Mariko Sato; Tsubasa Watanabe; Akira Anbai; Manabu Hashimoto; Yoshihiro Takai
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

Review 7.  Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas.

Authors:  Yukiko Nakahara; Hiroshi Ito; Jun Masuoka; Tatsuya Abe
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 8.  Theranostics in Boron Neutron Capture Therapy.

Authors:  Wolfgang A G Sauerwein; Lucie Sancey; Evamarie Hey-Hawkins; Martin Kellert; Luigi Panza; Daniela Imperio; Marcin Balcerzyk; Giovanna Rizzo; Elisa Scalco; Ken Herrmann; PierLuigi Mauri; Antonella De Palma; Andrea Wittig
Journal:  Life (Basel)       Date:  2021-04-10

Review 9.  Clinical Viability of Boron Neutron Capture Therapy for Personalized Radiation Treatment.

Authors:  Dominika Skwierawska; José Antonio López-Valverde; Marcin Balcerzyk; Antonio Leal
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

10.  Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET.

Authors:  Tadashi Watabe; Kohei Hanaoka; Sadahiro Naka; Yasukazu Kanai; Hayato Ikeda; Masanao Aoki; Eku Shimosegawa; Mitsunori Kirihata; Jun Hatazawa
Journal:  Ann Nucl Med       Date:  2017-04-24       Impact factor: 2.668

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.